

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2018/09/30	2017/12/31	2017/09/30
Balance Sheet			
Current assets			
Cash and cash equivalents	307,930	342,061	353,598
Current financial assets at amortised cost	87,143	0	0
Current investments in debt instrument without active market	0	283,586	285,160
Accounts receivable, net	26,781	67,304	62,491
Accounts receivable due from related parties, net	3,088	1,533	0
Other receivables	115	1,262	4,907
Current tax assets	649	2,225	2,120
Current inventories	73,495	46,206	53,530
Prepayments	20,531	11,586	29,397
Other current assets	10,444	9,928	6,098
Total current assets	530,176	765,691	797,301
Non-current assets			
Non-current financial assets at fair value through other comprehensive income	147,364	0	0
Non-current financial assets at cost	0	87,000	87,000
Property, plant and equipment	397,707	363,827	363,043
Intangible assets	13,638	1,957	1,960
Deferred tax assets	65,843	56,696	38,876
Other non-current assets	18,728	37,628	39,222
Total non-current assets	643,280	547,108	530,101
Total assets	1,173,456	1,312,799	1,327,402
Current liabilities			
Current contract liabilities	17,124	0	0
Accounts payable	34,908	9,567	13,788
Accounts payable to related parties	520	0	0
Other payables	71,400	114,951	45,058
Other payables to related parties	0	321	0
Other current liabilities	1,393	2,941	10,344
Total current liabilities	125,345	127,780	69,190
Non-current liabilities			
Deferred tax liabilities	0	0	0
Other non-current liabilities	41,111	41,153	2,225
Total non-current liabilities	41,111	41,153	2,225
Total liabilities	166,456	168,933	71,415
Share capital			
Ordinary share	1,099,545	1,121,180	1,121,180
Advance receipts for share capital	0	604	0
Total share capital	1,099,545	1,121,784	1,121,180
Capital surplus			
Capital surplus, additional paid-in capital	261,501	266,494	266,102
Capital surplus, treasury share transactions	0	2,812	2,812
Capital surplus, employee share options	38,404	29,856	27,045
Total capital surplus	299,905	299,162	295,959
Retained earnings			
Unappropriated retained earnings (accumulated deficit)	-428,614	-189,469	-73,541
Total retained earnings	-428,614	-189,469	-73,541
Other equity interest			
Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	36,164	0	0
Total other equity interest	36,164	0	0
Treasury shares	0	-87,611	-87,611
Equity attributable to former owner of business combination under common control	0	0	0
Equity attributable to non-controlling interest before business combination under common control	0	0	0
Total equity	1,007,000	1,143,866	1,255,987
Total liabilities and equity	1,173,456	1,312,799	1,327,402
Number of share capital awaiting retirement	0	0	0
Equivalent issue shares of advance receipts for ordinary share	0	36,500	0
Number of shares in entity held by entity and by its subsidiaries	0	2,200,000	2,200,000

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2018/3rd	2017/3rd	2018/01/01 To 2018/09/30	2017/01/01 To 2017/09/30
Income Statement				
Total operating revenue	59,166	126,340	125,053	225,598
Total operating costs	50,139	48,376	134,677	133,204
Gross profit (loss) from operations	9,027	77,964	-9,624	92,394
Gross profit (loss) from operations	9,027	77,964	-9,624	92,394
Operating expenses				
Selling expenses	7,311	6,587	13,148	13,639
Administrative expenses	12,062	12,193	30,584	33,711
Research and development expenses	51,208	40,393	156,492	125,435
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	920	0	1,551	0
Total operating expenses	71,501	59,173	201,775	172,785
Net operating income (loss)	-62,474	18,791	-211,399	-80,391
Non-operating income and expenses				
Total other income	3,679	4,285	12,973	18,114
Other gains and losses, net	482	-1,024	7,923	-11,015
Finance costs, net	74	0	222	0
Total non-operating income and expenses	4,087	3,261	20,674	7,099
Profit (loss) from continuing operations before tax	-58,387	22,052	-190,725	-73,292
Total tax expense (income)	-2,587	-57	-9,101	249
Profit (loss) from continuing operations	-55,800	22,109	-181,624	-73,541
Profit (loss)	-55,800	22,109	-181,624	-73,541
Other comprehensive income				
Components of other comprehensive income that will not be reclassified to profit or loss				
Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	12,943	0	7,374	0
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	0	0	-46	0
Total other comprehensive income	12,943	0	7,420	0
Total comprehensive income	-42,857	22,109	-174,204	-73,541
Basic earnings per share				
Total basic earnings per share	-0.51	0.20	-1.65	-0.67
Diluted earnings per share				
Total diluted earnings per share	0.00	0.20	0.00	0.00

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2018/01/01To2018/09/30	2017/01/01To2017/09/30
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-190,725	-73,292
Profit (loss) before tax	-190,725	-73,292
Depreciation expense	56,833	44,889
Amortization expense	1,429	753
Expected credit loss (gain) / Provision (reversal of provision) for bad debt expense	1,551	3,504
Interest expense	222	0
Interest income	-3,812	-3,680
Share-based payments	8,548	11,971
Loss (gain) on disposal of property, plan and equipment	8	-99
Impairment loss on non-financial assets	2,172	966
Other adjustments to reconcile profit (loss)	0	0
Total adjustments to reconcile profit (loss)	66,951	58,304
Decrease (increase) in accounts receivable	38,972	-42,667
Decrease (increase) in accounts receivable due from related parties	-1,555	24,472
Decrease (increase) in other receivable	936	-2,160
Decrease (increase) in inventories	-29,461	-4,101
Decrease (increase) in prepayments	-8,945	-9,408
Adjustments for decrease (increase) in other current assets	376	-272
Total changes in operating assets	323	-34,136
Increase (decrease) in contract liabilities	15,241	0
Increase (decrease) in accounts payable	25,341	-8,281
Increase (decrease) in accounts payable to related parties	520	0
Increase (decrease) in other payable	-43,979	3,245
Increase (decrease) in other payable to related parties	-321	-6
Adjustments for increase (decrease) in other current liabilities	335	4,616
Increase (decrease) in net defined benefit liability	-42	-46
Total changes in operating liabilities	-2,905	-472
Total changes in operating assets and liabilities	-2,582	-34,608
Total adjustments	64,369	23,696
Cash inflow (outflow) generated from operations	-126,356	-49,596
Income taxes refund (paid)	1,576	-212
Net cash flows from (used in) operating activities	-124,780	-49,808
Cash flows from (used in) investing activities		
Acquisition of financial assets at fair value through other comprehensive income	-24,200	0
Acquisition of financial assets at amortised cost	-109,000	0
Proceeds from disposal of financial assets at amortised cost	305,443	0
Acquisition of investments in debt instrument without active market	0	-190,487
Proceeds from disposal of investments in debt instrument without active market	0	390,726
Acquisition of financial assets at cost	0	-67,000
Acquisition of property, plant and equipment	-14,613	-46,604
Proceeds from disposal of property, plant and equipment	124	114
Increase in refundable deposits	-12	-420
Acquisition of intangible assets	-2,330	-371
Increase in other financial assets	-13,493	-5,107
Decrease in other financial assets	12,601	47,683
Increase in prepayments for business facilities	-52,710	-30,964
Increase in other prepayments	-15,184	-9,120
Interest received	4,023	3,771
Net cash flows from (used in) investing activities	90,649	92,221
Cash flows from (used in) financing activities		
Exercise of employee share options	0	1,414
Net cash flows from (used in) financing activities	0	1,414
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	-34,131	43,827
Cash and cash equivalents at beginning of period	342,061	309,771
Cash and cash equivalents at end of period	307,930	353,598
Cash and cash equivalents reported in the statement of financial position	307,930	353,598
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

